Results 101 to 110 of about 9,424 (215)
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Obesity Reviews, Volume 27, Issue 11, November 2026.ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source
Multitarget Drug Design for Cardiovascular Disease: Bridging Chemistry and Medicine
ChemMedChem, Volume 21, Issue 19, 14 October 2026.Many pathophysiological pathways associated with cardiovascular diseases involve multiple drug targets. This article reviews recent advances in the development of pharmacological compounds capable of simultaneously modulating multiple mechanisms. Multitarget drugs offer a promising therapeutic approach for complex cardiovascular disorders, including ...
Gyuzel Y. Mitronova +3 more
wiley +1 more source
Dynamics of GFP-SGLT1 in COS-7 Cells
, 2004 We recently showed that in Caco-2 cells the high affinity Na+-/Dglucose cotransporter (SGLTl) resides in intracellular endosomes which are attached to microtubules and therefore proposed that the activity of SGLTl is regulated by intracellular ...
Scharlau, D. +3 more
core
SGLT1-Mediated Transport in Caco-2 Cells Is Highly Dependent on Cell Bank Origin
, 2017 The human colon adenocarcinoma (Caco-2) cell line is a well-established in vitro model for studying transport phenomena for prediction of intestinal nutrient and drug absorption.
Laghmoch, Abdel M +11 more
core +1 more source
Toxicology Reports, 2018 The objective was to evaluate the effect of black bean protein fraction (PFRA), and its derived peptides on glucose uptake, SGLT1 and GLUT2 expression and translocation on Caco-2 cells.
Luis Mojica +2 more
doaj +1 more source
Therapeutic Advancements: the role of SGLT1 inhibitors in the current management of type 2 Diabetes
, 2021 Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, 2021, Universidade de Lisboa, Faculdade de Farmácia.Os co-transportadores de Na+-glucose, SGLT1 e SGLT2, transportam a glucose através das membranas epiteliais.
Pereira, Carla Alexandra Guerreiro
core
, 2020 Sodium/glucose cotransporter 1 (SGLT1), an essential active glucose transport protein that helps maintain high intracellular glucose levels, was previously shown to interact with epidermal growth factor receptor (EGFR); the SGLT1-EGFR interaction ...
Xianglin Yuan (220063) +13 more
core
Regulation des Na+-D-Glucose Kotranporters SGLT1 im Dünndarm nach bariatrischen Operation und durch von Protein RS1 (RSC1A1) abgeleitete Peptide [PDF]
, 2015 Bariatric surgery represents the first-line treatment for morbid obesity, resulting in weight loss and improved diabetes control. The positive effect of bariatric surgery on type-2 diabetes is unclear.
Rikkala, Prashanth Reddy
core +1 more source
In caco-2 cells, most of the "apical" SGLT1 resides in intracellular, microtubuli-associated vesicles [PDF]
, 2002 We investigated the distribution of the endogenous sodium/D-glucose cotransporter (SGLT1) in polarized Caco-2 cells, a model for enterocytes. A cellular organelle fraction was separated by free flow electrophoresis.
Khoursandi, S., Kinne, R., Kipp, H.
core +1 more source
Differential expression patterns of SGLT1 and SGLT2 in feline and human tissues
In 2022 and 2023, two sodium-glucose cotransporter-2 inhibitors, bexagliflozin and velagliflozin, entered the veterinary field for treatment of feline diabetes mellitus.
Martha Campbell-Thompson +3 more
core +1 more source